- Second-line treatment of advanced NSCLC: Comparison of efficacy of erlotinib and chemotherapy2013 | Faculty of Medicine in Pilsen
- New options of expensive pneumo-oncological therapy for advanced non-small-cell lung carcinoma (NSCLC) in the first line based on morphological and molecular genetic diagnosis in the Czech Republic2012 | Central Library of Charles University, Faculty of Medicine in Pilsen, First Faculty of Medicine
- New options for biologically targeted therapy of advanced non-small-cell lung cancer - sunitinib and sorasfenib2010 | Central Library of Charles University
- First-line immunotherapy in NSCLC - what brought 20182018 | Faculty of Medicine in Pilsen
- Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice2013 | Faculty of Medicine in Pilsen
- Is anticancer immunotherapy break-trough in lung cancer therapy?2019 | First Faculty of Medicine
- Is anticancer imunotherapy break-trough in lung cancer therapy?2020 | First Faculty of Medicine
- Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis2007 | Third Faculty of Medicine
- Effect of clinical parameters on second- and third-line erlotinib treatment of EGFR wild type patients with advanced NSCLC2019 | Central Library of Charles University, Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine